Trials / Completed
CompletedNCT01422187
A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center trial to further extend the assessment of the safety and efficacy of taliglucerase alfa in adult subjects (≥18 years old) with Gaucher disease who have enrolled in Protocol PB-06-003. Subjects will continue to receive an intravenous (IV) infusion of taliglucerase alfa every two weeks. The duration of treatment will be a maximum of 21 months or until taliglucerase alfa is commercially available to the subject at the discretion of the Sponsor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Taliglucerase alfa | Taliglucerase infusion every two weeks for 21 months |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2014-05-01
- Completion
- 2014-09-01
- First posted
- 2011-08-23
- Last updated
- 2023-04-19
- Results posted
- 2015-12-14
Source: ClinicalTrials.gov record NCT01422187. Inclusion in this directory is not an endorsement.